Results 71 to 80 of about 27,163 (253)

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis [PDF]

, 2015
Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics.
D'Amico, Roberto, Del Giovane, Cinzia, Filippini, Graziella, Salanti, Georgia, Tramacere, Irene   +4 more
core   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Iranian Journal of Allergy, Asthma and Immunology, 2018
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and
Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad   +6 more
doaj   +1 more source

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

PLoS ONE, 2021
ObjectiveTo describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.MethodsAn observational ...
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, J Olascoaga, A Pato, L Ramió-Torrentà, V Meca-Lallana, M A Hernández, M E Marzo, J C Álvarez-Cermeño, A Rodríguez-Antigüedad, X Montalbán, O Fernández, Spanish GILENYA Registry Investigators   +13 more
doaj   +1 more source

Combination Therapy With Fingolimod and Neural Stem Cells Promotes Functional Myelination [PDF]

, 2019
Myelination, which occurs predominantly postnatally and continues throughout life, is important for proper neurologic function of the mammalian central nervous system (CNS).
Ciric, Bogoljub, Li, Xing, Lu, Xin-Yu, Ma, Cun-Gen, Rostami, A. M., Ye, Ze-Qin, Zhang, Guang-Xian, Zhang, Yuan   +7 more
core   +1 more source

Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]

, 2010
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Bartholomaus I., Ben-Nun A., Bennett JL, Bielekova B., Bradl M., Chabas D., De Jager PL, De Jager PL, Dornmair K., Ferguson B., Flügel A., Frischer JM, Gold R., Gregersen JW, Han MH, Hohlfeld R., Hohlfeld R., Junker A., Kerschensteiner M., Kerschensteiner M., Kinoshita M., Korn T., Krishnamoorthy G., Kuhlmann T., Kümpfel T., Kümpfel T., Kümpfel T., Lennon VA, Linington C., Lock C., Mathey EK, Misgeld T., Platten M., Pollinger B., Polman CH, Reinhard Hohlfeld, Schluesener HJ, Seitz S., Sobottka B., Stadelmann C., Trapp BD, Trapp BD, Wiendl H., Wiendl H., Zipp F.   +44 more
core   +1 more source

Post-ischaemic immunological response in the brain: targeting microglia in ischaemic stroke therapy [PDF]

, 2020
Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke.
Chen, Ruoli, Dallas, Mark L., Jenkins, Stuart, Rawlinson, Charlotte, Thei, Laura   +4 more
core   +3 more sources

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion [PDF]

, 2017
Neurotransmission and secretion of hormones involve a sequence of protein/lipid interactions with lipid turnover impacting on vesicle trafficking and ultimately fusion of secretory vesicles with the plasma membrane.
A Flašker, A Ruiz, B Balatoni, B Czech, B Davletov, B Rituper, BA Davletov, C Rickman, C Wu, CA Foster, CF Brosnan, D Marsolais, E Connell, E Connell, E Neher, ET Kavalali, ET Kavalali, EV Mosharov, F Darios, F Safarian, J Vargas-Medrano, K Chiba, K Hu, KL Arendt, L Svennerholm, LM Gutierrez, M Holt, M Rupnik, M Schröder, M Stenovec, MD Ward, N Takasugi, N Vardjan, NC Hait, P O’Connor, R Brunkhorst, R Cipriani, R Deogracias, RM Wightman, S Jurado, S Lipovšek, S Rossi, S Trkov, V Brinkmann, V García-Martínez, V García-Martínez, VT Cruz, X He, Y Wei, YA Hannun, YD Fragoso   +50 more
core   +4 more sources

Real‐World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease‐Modifying Therapy in Pediatric Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective To assess real‐world effectiveness of switching disease‐modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Methods Of 2615 pediatric‐onset demyelinating disease patients at 12 clinics in the United States (US) Network of Pediatric
Aaron W. Abrams, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie A. Benson, Eva‐Chava M. Bernfeld, Leigh E. Charvet, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Kimberly O'Neill, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, John Rose, Alice Rutatangwa, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, Kristen M. Krysko, on behalf of the US Network of Pediatric MS Centers   +27 more
wiley   +1 more source